from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A nonsteroidal anti-inflammatory drug indicated for the treatment of ocular inflammation and pain after cataract surgery.


Sorry, no etymologies found.


  • The drug couples a lower concentration of the drug bromfenac, which is marketed by

    Philadelphia Business News - Local Philadelphia News | The Philadelphia Business Journal

  • Host and damages need bromelain genotype and control that bromfenac episodes.

    Rudy: Iraq Is "In The Hands Of Other People"

  • InSite Vision is advancing a second product candidate, known as ISV-101, that utilizes a low-concentration of bromfenac enabled by DuraSite for the treatment of dry eye disease.

  • BromSite combines a lower dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision's DuraSite drug delivery technology and is intended to reduce the pain and inflammation associated with ocular surgery.

  • Study results showed that the mean concentration of bromfenac in the aqueous humor of patients in BromSite's group was more than twice greater compared to those patients in Bromday's group with a P-Value of p=0.0032.

  • Most physicians believe that a higher penetration of bromfenac into the ocular tissues of the eye may reduce the risk of cystoid macular edema, or CME, as a result of ocular surgery.

  • Results of the Lissamine Green test in the Phase 2 study revealed statistical significance for low-dose bromfenac versus the patients 'baseline scores starting as early as Day 14 and sustained through Day 52, ten days post treatment. Featured News and Stories

  • The study was designed to investigate the effects of low-dose bromfenac compared to baseline on the objective signs of conjunctival staining (Lissamine Green test) and corneal staining (Fluorescein test), as well as subjective symptoms (OSDI and patient's most bothersome ocular symptoms), when administered under normal environmental conditions. Featured News and Stories

  • June 8/PRNewswire-FirstCall/-- ISTA Pharmaceuticals, Inc., today announced positive results from a proof-of-concept Phase 2 clinical study in subjects with dry eye disease (keratoconjuctivitis sicca) using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom (R) (bromfenac ophthalmic solution) 0. 09%. Featured News and Stories

  • ISTA's proof-of-concept, Phase 2 bromfenac study enrolled 38 patients who exhibited signs and symptoms consistent with moderate dry eye disease. Featured News and Stories


Log in or sign up to get involved in the conversation. It's quick and easy.